USD
+$0.00
(+0.00%
)At Close (As of Sep 5, 2025)
$6.35B
Market Cap
-
P/E Ratio
-0.17
EPS
$48.45
52 Week High
$16.50
52 Week Low
HEALTHCARE
Sector
Field | Value (CNY) |
---|---|
Gross Profit | $952M |
Total Revenue | $981M |
Cost Of Revenue | $29M |
Costof Goods And Services Sold | $29M |
Operating Income | -$370M |
Selling General And Administrative | $187M |
Research And Development | $947M |
Operating Expenses | $1.3B |
Investment Income Net | - |
Net Interest Income | -$27M |
Interest Income | $38M |
Interest Expense | $64M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $93M |
Income Before Tax | -$395M |
Income Tax Expense | $10M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$406M |
Comprehensive Income Net Of Tax | - |
Ebit | -$331M |
Ebitda | -$238M |
Net Income | -$405M |
Field | Value (CNY) |
---|---|
Total Assets | $2.6B |
Total Current Assets | $1.5B |
Cash And Cash Equivalents At Carrying Value | $1.2B |
Cash And Short Term Investments | $1.2B |
Inventory | $6.6M |
Current Net Receivables | $99M |
Total Non Current Assets | $1.1B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $76M |
Intangible Assets Excluding Goodwill | $76M |
Goodwill | $25M |
Investments | - |
Long Term Investments | $34M |
Short Term Investments | $5.4M |
Other Current Assets | $132M |
Other Non Current Assets | - |
Total Liabilities | $2.3B |
Total Current Liabilities | $1.2B |
Current Accounts Payable | $92M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $779M |
Total Non Current Liabilities | $1.2B |
Capital Lease Obligations | $30M |
Long Term Debt | $869M |
Current Long Term Debt | $770M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.7B |
Other Current Liabilities | $255M |
Other Non Current Liabilities | $6.3M |
Total Shareholder Equity | $264M |
Treasury Stock | - |
Retained Earnings | -$5.8B |
Common Stock | $214K |
Common Stock Shares Outstanding | $302M |
Field | Value (CNY) |
---|---|
Operating Cashflow | -$111M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $93M |
Capital Expenditures | $24M |
Change In Receivables | - |
Change In Inventory | $9.6M |
Profit Loss | - |
Cashflow From Investment | -$362M |
Cashflow From Financing | $315M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $0 |
Dividend Payout Common Stock | $0 |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $0 |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$395M |
Field | Value (CNY) |
---|---|
Gross Profit | $952M |
Total Revenue | $981M |
Cost Of Revenue | $29M |
Costof Goods And Services Sold | $29M |
Operating Income | -$370M |
Selling General And Administrative | $187M |
Research And Development | $947M |
Operating Expenses | $1.3B |
Investment Income Net | - |
Net Interest Income | -$27M |
Interest Income | $38M |
Interest Expense | $64M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $93M |
Income Before Tax | -$395M |
Income Tax Expense | $10M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$406M |
Comprehensive Income Net Of Tax | - |
Ebit | -$331M |
Ebitda | -$238M |
Net Income | -$405M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.